Search Results - "Harvey, R.D."

Superiority of Rapamycin Over Tacrolimus in Preserving Nonhuman Primate Treg Half‐Life and Phenotype After Adoptive Transfer by Singh, K., Stempora, L., Harvey, R. D., Kirk, A. D., Larsen, C. P., Blazar, B. R., Kean, L. S.

“…Many critical issues remain concerning how best to deploy adoptive regulatory T cell (Treg) immunotherapy to the clinic. These include a determination of their…”
Get full text

Safety Profile of Oral Ixazomib: Experience from 761 Patients (Pts) Across 14 Phase 1 or Phase 1/2 Clinical Studies by Lonial, S, Colson, K, Harvey, R.D, Kumar, S, Hui, A.-M, Liu, G, Berg, D, Richardson, P

Get full text

1230 POSTER A Phase 1 and Pharmacokinetic Study of Ganetespib (STA-9090), a Heat Shock Protein 90 Inhibitor, in Combination With Docetaxel in Subjects With Advanced Solid Tumour Malignancies by Harvey, R.D, Lewis, C.M, Kauh, J.S, Owonikoko, T.K, Akintayo, A, Karol, M, Teofilovici, F, Lufkin, J.M, Khuri, F.R, Ramalingam, S.S

Get full text

Structure of vesicles formed from non-ionic dialkylglycerol poly(oxyethylene) ether surfactants: effect of electrolyte and cholesterol by Harvey, R.D., Barlow, D.J., Brain, A.P.R., Heenan, R.K., Zuberi, S., Zuberi, T., Lawrence, M.J.

“…Five non-ionic dialkylglycerol poly(oxyethylene) ether surfactants, designated 2C m E n (where m, the number of carbons in each alkyl chain = 16 or 18, and n,…”
Get full text

Dose derivation of oral anticancer agents: Tolerability in late phase registration trials by McCabe, C., Bryson, E., Harvey, R.D.

Get full text

A0532 - Ongoing phase II study of EZH2 inhibitor CPI-0209 in patients with advanced solid tumors including metastatic castration-resistant prostate cancer (mCRPC) or hematologic malignancies by Kwiatek, M., Gutierrez, M., Harvey, R.D., Sullivan, R.J., Walter, H.S., Faulhaber, N., Jauch-Lembach, J., Kann, L., Lakhani, N.J.

Get full text

Ongoing phase II study of EZH2 inhibitor CPI-0209 in patients with advanced solid tumors including metastatic castration-resistant prostate cancer (mCRPC) or hematologic malignancies by Kwiatek, M., Gutierrez, M., Harvey, R.D., Sullivan, R.J., Walter, H.S., Faulhaber, N., Jauch-Lembach, J., Kann, L., Lakhani, N.J.

Get full text

469P A phase I study of palbociclib in combination with cisplatin or carboplatin in advanced solid malignancies by Alese, O.B., Bilen, M.A., Hitron, E., Lewis, C., Collins, H.H., Scott, S., Carthon, B., Cao, Y., Switchenko, J.M., Harvey, R.D., Owonikoko, T.K.

Get full text

Enhancing Performance of Thermoelectric Coolers Through the Application of Distributed Control by Harvey, R.D., Walker, D.G., Frampton, K.D.

“…The primary drawback of thermoelectric coolers (TECs) for electronics cooling applications is their thermodynamic inefficiency due to material limitations. The…”
Get full text

Preliminary Clinical Data From Ongoing Phase 2 Study With Enhancer of Zeste Homolog 2 (EZH2) Inhibitor CPI-0209 in Patients With Advanced Solid Tumors or Hematologic Malignancies by Kindler, H., Harvey, R.D., Duska, L.R., Gandhi, L., Sullivan, R.J., Gastinne, T., Kwiatek, M., García-Sancho, A.M., Hadar, N., Kann, L., Faulhaber, N., Drescher, C.

Get full text

25P Impact of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma (the MEMOIR study): A propensity score-matched analysis by Qian, D.C., Kleber, T., Brammer, B., Xu, K.M., Switchenko, J.M., Janopaul-Naylor, J.R., Zhong, J., Yushak, M.L., Harvey, R.D., Paulos, C.M., Lawson, D.H., Khan, M.K., Kudchadkar, R.R., Buchwald, Z.S.

Get full text

Early results of pegvorhyaluronidase alfa (PEGPH20; PVHA) + pembrolizumab therapy in patients (Pts) with relapsed/refractory gastric/gastroesophageal junction (GEJ) adenocarcinoma by Harvey, R.D., Murphy, A., Kim, E., Tejani, M.A., Wu, W., Pham, E.L., Muhsin, M.

Get full text

Pilot Study of Potential Activation of c-MYC by Aurora Kinase A in Everolimus-Resistant Localized Esophageal Cancer Treated with XELOX followed by Carboplatin/Radiation by Saba, N.F., Force, S., Staley, C.A., Fernandez, F., Willingham, F.F., Pickens, A., Cardona, K., Chen, Z., Goff, L., Cardin, D., Lambright, E., Nesbitt, J.C., Higgins, K.A., Harvey, R.D., Owonikoko, T.K., Ramalingam, S., Shin, D.M., Beitler, J.J., El-rayes, B., Salaria, S., El-Rifai, W., Landry, J.C., Chakravarthy, A.B.

Get full text

Sites of metastasis and association with clinical outcome (CO) in advanced stage cancer patients (pts) treated with immunotherapy (IO) by Bilen, M.A., Shabto, J.M., Martini, D.J., Liu, Y., Lewis, C., Collins, H.H., Akce, M., Kissick, H., Carthon, B.C., Shaib, W.L., Alese, O.B., Steuer, C.E., Wu, C., Lawson, D.H., Kudchadkar, R., Master, V., El-Rayes, B., Ramalingam, S.S., Owonikoko, T.K., Harvey, R.D.

Get full text

Sarcopenia and inflammation predicts survival in advanced stage cancer patients (pts) treated with immunotherapy (IO) by Bilen, M.A., Martini, D.J., Shabto, J.M., Liu, Y., Khan, A.I., Williams, M.A., Lewis, C., Collins, H.H., Kissick, H., Carthon, B.C., Akce, M., Shaib, W.L., Alese, O.B., Lawson, D.H., Kudchadkar, R., El-Rayes, B., Ramalingam, S.S., Owonikoko, T.K., Harvey, R.D., Master, V.A.

Get full text

Memory effects of monolayers and vesicles formed by the non-ionic surfactant, 2C 18E 12 by Barlow, D.J., Hollinshead, C.M., Harvey, R.D., Kudsiova, L., Lawrence, M.J.

“…The behaviour of monolayers and bilayers formed by the dialkyl chain non-ionic surfactant, 1,2-di- O-octadecyl- rac-glycerol-3- ω-methoxydodecaethylene glycol…”
Get full text

Commentary on Perrone et al.: ‘Vitamin C: not for breakfast anymore…if you have myeloma’ by Harvey, R D, Nettles, J, Wang, B, Sun, S-Y, Lonial, S

Get full text

Memory effects of monolayers and vesicles formed by the non-ionic surfactant, 2C18E12 by BARLOW, D. J, HOLLINSHEAD, C. M, HARVEY, R. D, KUDSIOVA, L, LAWRENCE, M. J

Get full text

Effects of surface pressure on the structure of the monolayer formed at the air/water interface by a non-ionic surfactant by Ma, G., Barlow, D.J., Hollinshead, C.M., Harvey, R.D., Webster, J.R.P., Lawrence, M.J.

“…The monolayer formed at an air/water interface by the synthetic non-ionic surfactant, 1,2-di- O-octadecyl- rac-glyceryl-3-( ω-methoxydodecakis (ethylene…”
Get full text

Elotuzumab by Harvey, R.D., Gleason, C., Lewis, C., Lonial, S.

Get full text